M. Carducci

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Michael A Carducci, M. A. Carducci, M. Carducci, Michael Anthony Carducci, M A Carducci, Michael Carducci, M.a. Carducci, M Carducci, Michael A. Carducci
Publication record
798 papers · 52,102 citations · H-index 103

PAPERS

Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.
202417 citationsauthor #16
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
202435 citationsauthor #9
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
20248 citationsauthor #13
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
202415 citationsauthor #10
Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies.
20240 citationsauthor #7
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).
20240 citationsauthor #18
Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).
20246 citationsauthor #16
Muscadine grape skin extract in men with biochemically recurrent prostate cancer: A phase III, randomized, multicenter, placebo-controlled clinical trial.
20242 citationsauthor #19
Effect of cerebral dopamine metabolism genetic polymorphism on patient-reported quality-of-life (QOL): An analysis of the E3805 CHAARTED trial.
20231 citationsauthor #7
Clonal hematopoiesis of indeterminate potential (CHIP) and association with response to bipolar androgen therapy (BAT).
20230 citationsauthor #6
CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.
202310 citationsauthor #9
Role of bromodomain and extraterminal (BET) proteins in prostate cancer
202313 citationsauthor #3
A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
20234 citationsauthor #1
The ENGAGE study: evaluation of a conversational virtual agent that provides tailored pre-test genetic education to cancer patients
20238 citationsauthor #17
Abstract B067: CRM1 inhibitor selinexor induces DNA damage repair-related vulnerability in prostate cancer cells
20230 citationsauthor #10
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).
20231 citationsauthor #10
Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.
20230 citationsauthor #16
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
202311 citationsauthor #10
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
202344 citationsauthor #14
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
202317 citationsauthor #14
Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer.
20230 citationsauthor #15
Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma.
20233 citationsauthor #1
Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).
20230 citationsauthor #4
Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.
20234 citationsauthor #10
ORCHID: A phase II study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations
20238 citationsauthor #7
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.
20232 citationsauthor #8
Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).
20236 citationsauthor #10
Abstract P139: Behavioral Weight Loss Programs for Cancer Survivors: A Non-Randomized Clinical Trial
20230 citationsauthor #9
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
202320 citationsauthor #9
Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52].
20220 citationsauthor #6
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
202216 citationsauthor #18
The international penile advanced cancer trial (InPACT): The first phase III trial for squamous carcinoma of the penis with regional lymph node metastases.
20228 citationsauthor #7
Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study
202213 citationsauthor #11
LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial
202281 citationsauthor #19
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
202228 citationsauthor #9
Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer
202213 citationsauthor #15
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics
202223 citationsauthor #10
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
202234 citationsauthor #9
Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
20229 citationsauthor #16
Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
20229 citationsauthor #6
A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.
20221 citationsauthor #2
Oncologist Peer Comparisons as a Behavioral Science Strategy to Improve Hospice Utilization
20224 citationsauthor #6
EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration.
20223 citationsauthor #13
PACCT: An intervention to improve communication quality and clinical trial invitations for Black and White men with prostate cancer.
20220 citationsauthor #8
Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805
20229 citationsauthor #4
Abstract 1505: Exploring the role of CRM1 in DNA repair pathway in prostate cancer cells
20220 citationsauthor #10
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
202231 citationsauthor #17
Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?
202214 citationsauthor #2
Physicians' use of plain language during discussions of prostate cancer clinical trials with patients.
202211 citationsauthor #7
ORCHID: A phase II study of olaparib in metastatic renal cell carcinoma patients harboring a BAP1 or other DNA repair gene mutations.
20224 citationsauthor #4
A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testing
20224 citationsauthor #10
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
202187 citationsauthor #17
Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine
20213 citationsauthor #7
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review.
202113 citationsauthor #6
ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).
202111 citationsauthor #3
Abstract LB102: Effect of mistletoe extract on growth and proliferation of prostate cancer cells
20210 citationsauthor #10
Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.
20214 citationsauthor #15
COMBAT-CRPC: Concurrent administration of bipolar androgen therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC).
202110 citationsauthor #8
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
2021103 citationsauthor #25
EA8185: Phase II study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), ECOG-ACRIN/nrg collaboration.
20213 citationsauthor #13
End-of-Life Characteristics Associated With Short Hospice Length of Stay for Patients With Solid Tumors Enrolled in Phase I Clinical Trials.
20215 citationsauthor #6
Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial
202156 citationsauthor #11
What are survivorship care plans failing to tell men after prostate cancer treatment?
20215 citationsauthor #11
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED study.
202135 citationsauthor #15
Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology
20217 citationsauthor #11
Development and pilot test of a physician-focused cancer clinical trials communication training intervention
20216 citationsauthor #8
PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).
20212 citationsauthor #15
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.
202156 citationsauthor #14
Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer
202139 citationsauthor #23
Effects of Behavioral Weight Loss and Metformin on Insulin-like Growth Factors in Cancer Survivors: A Randomized Trial.
202117 citationsauthor #16
Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.
202115 citationsauthor #9
PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
202116 citationsauthor #13
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).
202116 citationsauthor #6
Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
202027 citationsauthor #4
FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC).
202024 citationsauthor #9
Reply by Authors.
20200 citationsauthor #10
TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC).
20202 citationsauthor #17
RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).
20201 citationsauthor #4
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
202026 citationsauthor #26
Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805).
20202 citationsauthor #6
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
202063 citationsauthor #12
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
2020937 citationsauthor #19
The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer.
20201 citationsauthor #15
End-of-life characteristics associated with short hospice length of service for patients with solid tumors enrolled on phase I clinical trials.
20200 citationsauthor #7
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
202078 citationsauthor #8
Prostate cancer survivorship care plans: What we are failing to tell men after treatment?
20200 citationsauthor #11
Changes in the place of death for older adults with cancer: Reason to celebrate or a risk for unintended disparities?
202019 citationsauthor #6
Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer.
202028 citationsauthor #7
Abstract 2410: Supraphysiological androgens induce ferroptotic cell death in prostate cancer cells
20200 citationsauthor #8
566P A multicenter, open-label, dose-escalation, first-in-man study of MetAP2 inhibitor M8891 in patients with advanced solid tumours
20201 citationsauthor #1
Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)
202015 citationsauthor #6
Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).
202069 citationsauthor #12
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
2020271 citationsauthor #19
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
202070 citationsauthor #4
Modes of Failure Following Metastasis Directed Therapy in Patients with Oligometastatic Hormone Sensitive Prostate Cancer: A Multi-institutional Analysis
20200 citationsauthor #11
Supraphysiological testosterone induces ferroptosis and activates NF-kappaB mediated immune pathways in prostate cancer through nucleophagy
20202 citationsauthor #26
687TiP ARC-6: A phase Ib/II, open-label, randomized platform study evaluating the efficacy and safety of AB928-based treatment combinations in patients with metastatic castrate resistant prostate cancer
20200 citationsauthor #11
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
202067 citationsauthor #10
Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.
202081 citationsauthor #9
Problem Solving to Enhance Clinical Trial Participation Utilizing a Framework-Driven Approach.
20203 citationsauthor #3

TIMELINE

1995 344 citations

1996 197 citations

1997 451 citations

1998 147 citations

1999 1,656 citations

2000 805 citations

2001 1,051 citations

2002 839 citations

2003 739 citations

2004 1,107 citations

2005 633 citations

2006 3,415 citations

2007 5,270 citations

2008 3,560 citations

2009 2,228 citations

2010 1,265 citations

2011 3,431 citations

2012 2,590 citations

2013 1,315 citations

2014 4,432 citations

2015 4,285 citations

2016 4,498 citations

2017 1,565 citations

2018 1,994 citations

2019 1,353 citations

2020 1,896 citations

2021 509 citations

2022 315 citations

2023 152 citations

2024 83 citations

Unknown 0 citations

M. Carducci

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT